Status:
RECRUITING
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Bladder Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world...
Eligibility Criteria
Inclusion
- Prescribed and scheduled treatment with ADSTILADRIN per physician discretion or received the first instillation of ADSTILADRIN per physician discretion after 5 September 2023 but prior to site activation
- Signed and dated ICF.
- Age 18 years or older at day ICF is signed.
Exclusion
- Currently enrolled in a clinical trial.
- Participants who have previously been treated with ADSTILADRIN in the context of a clinical trial
- Participant is pregnant or breastfeeding.
Key Trial Info
Start Date :
September 15 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06026332
Start Date
September 15 2023
End Date
December 31 2027
Last Update
September 17 2025
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
Banner Health MD Anderson Cancer Center
Gilbert, Arizona, United States, 85234
2
Mayo Clinic Arizona
Phoenix, Arizona, United States, 85054
3
Arkansas Urology, North Little Rock
Little Rock, Arkansas, United States, 72211
4
Urology Associates of Central California
Fresno, California, United States, 93720